What’s the current market cap for Eton Pharmaceuticals stock?

Eton Pharmaceuticals (ETON) has a market cap of $1bn as of July 02, 2026.

What is the P/E ratio for Eton Pharmaceuticals stock?

The price to earnings (P/E) ratio for Eton Pharmaceuticals (ETON) stock is 0 as of July 02, 2026.

Does Eton Pharmaceuticals stock pay dividends?

No, Eton Pharmaceuticals (ETON) stock does not pay dividends to its shareholders as of July 02, 2026.

When is the next Eton Pharmaceuticals dividend payment date?

Eton Pharmaceuticals (ETON) stock does not pay dividends to its shareholders.

What is the beta indicator for Eton Pharmaceuticals?

Eton Pharmaceuticals (ETON) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Eton Pharmaceuticals stock | $ETON Share Price

13:30

15:10

16:45

18:25

20:00

About Eton Pharmaceuticals

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.

Ticker

$ETON

Sector

Health

Primary listing

NASDAQ

Employees

Headquarters

Deer Park, United States

Website

www.etonpharma.com

ETON Metrics

BasicAdvanced

$1bn

-$0.05

0.82

What the Analysts think about ETON

Analyst ratings (Buy, Hold, Sell) for Eton Pharmaceuticals stock.

Bulls say / Bears say

FDA approved Desmoda, Eton’s proprietary oral desmopressin formulation, on February 25, 2026, marking the first FDA-approved desmopressin oral solution and expected to generate peak annual sales of $30–50 million. (Reuters)

Eton reported Q1 2026 revenue of $24.3 million, a 40 % year-over-year increase and 10.7 % above street forecasts, demonstrating strong demand across its commercial portfolio. (Reuters)

Eton licensed U.S. marketing rights to an ultra-rare disease product candidate under FDA review, targeting a mid-2026 launch to leverage its established commercial infrastructure and expand its rare disease portfolio. (Reuters)

Eton’s Q1 2026 EPS of $0.05 missed expectations by 73.7 %, reflecting profitability pressures despite robust revenue growth. (Reuters)

Margin compression from international sales and rising G&A and R&D expenses pose headwinds to Eton’s earnings margin expansion. (Reuters)

ETON shares have rallied approximately 94.5 % year-to-date and trade within 1 % of their 52-week high, suggesting limited near-term upside and elevated valuation risk. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 27 Jun 2026.

ETON Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

ETON Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

Eton reported Q1 2026 revenue of $24.3 million, a 40 % year-over-year increase and 10.7 % above street forecasts, demonstrating strong demand across its commercial portfolio. (Reuters)

Eton’s Q1 2026 EPS of $0.05 missed expectations by 73.7 %, reflecting profitability pressures despite robust revenue growth. (Reuters)

Margin compression from international sales and rising G&A and R&D expenses pose headwinds to Eton’s earnings margin expansion. (Reuters)

ETON shares have rallied approximately 94.5 % year-to-date and trade within 1 % of their 52-week high, suggesting limited near-term upside and elevated valuation risk. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 27 Jun 2026.

About Eton Pharmaceuticals

Ticker

Employees

ETON Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about ETON

Analyst Ratings

Bulls say / Bears say

ETON Financial Performance

Income Statement

ETON Earnings Performance

Earnings per share (EPS)

ETON News

Eton Pharmaceuticals Q1 Earnings Call Highlights

Buy $ETON

Lightyear

Legal

Work with us

Bulls say / Bears say

Eton Pharmaceuticals/$ETON

About Eton Pharmaceuticals

Ticker

Employees

ETON Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about ETON

Analyst Ratings

Bulls say / Bears say

ETON Financial Performance

Income Statement

ETON Earnings Performance

Earnings per share (EPS)

ETON News

Eton Pharmaceuticals Q1 Earnings Call Highlights

What’s the current market cap for Eton Pharmaceuticals stock?

What is the P/E ratio for Eton Pharmaceuticals stock?

Does Eton Pharmaceuticals stock pay dividends?

When is the next Eton Pharmaceuticals dividend payment date?

What is the beta indicator for Eton Pharmaceuticals?

Bulls say / Bears say